At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Aromatase Inhibitors Modify the Gut Microbiome Effecting Estrogen Bioavailability
In Brief
An observational study evaluating Fecal swab collection and Blood samples for Breast Cancer. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this research is to study the bacteria in participants' gut before receiving a medicine called an aromatase inhibitor for breast cancer and after participants receive medicine for breast cancer.
Study Details
Timeline
Arms & Interventions
Participants will receive their standard of care for breast cancer treatment which includes an aromatase inhibitor. Pre-study assessments will be done at baseline as well as stool and blood samples at baseline, then again at 4 weeks and at 12 weeks during the course of the trial.
Interventions
Participants will collect fecal sample at home and either mail in the sample, or drop it off at the lab
Participants will have approximately 1 teaspoon of blood withdrawn from a vein, for research, on 2 different occasions. The total amount of blood withdrawn during the study will be approximately 2 teaspoons.